BUSINESS
Trump signs order to slash US drug prices using global benchmarking, lacks clarity on generic drugs
India, which supplies nearly 40% of U.S. generics, exported $8.73 billion worth of drugs to the U.S. in 2024. Any disruption in pricing would eat into the already thin profit margins.
BUSINESS
Cautious Indian pharma awaits clarity on Trump’s prescription drug plan
Indian generic drugmakers typically operate on thin EBITDA margins of 5-15 percent on average for their base business in US, and even a small reduction in price could lead to financial unviability.
BUSINESS
India mobilizes emergency health systems amid Operation Sindoor
Union Health Minister J.P. Nadda chaired a high-level review meeting to assess the country’s emergency health systems preparedness, signaling a full-spectrum mobilization of medical infrastructure in anticipation of potential conflict-related casualties.
BUSINESS
Drugmakers, hospitals prepared for medical emergencies along border states
Sources with the influential Indian pharmaceutical body told Moneycontrol that the industry is always geared up to support the government with necessary medicines, and medical consumables.
BUSINESS
Biocon Q4 net profit surges 153%, biosimilars, generics drive growth
The company said its Board approved a fundraise of up to Rs 4,500 crore and is also evaluating a potential merger of Biocon Biologics with the parent company.
BUSINESS
Agilent opens India Solution Center to bolster scientific innovation & localized R&D
The center will serve as a hub for collaborative R&D, training, and proof-of-concept demonstrations, with dedicated zones for chromatography, mass spectrometry, spectroscopy, genomics, and cell analysis.
BUSINESS
USFDA expands unannounced inspections abroad, raising stakes for Indian drugmakers
The USFDA conducts around 3,000 foreign inspections annually, many of which involve Indian pharmaceutical plants that supply a substantial share of generic drugs to the U.S. market.
BUSINESS
Alembic Pharma eyes FY26 growth with optimism across domestic, US, and global markets
'As we ramp up our revenues and my facilities get optimally utilised, my EBITDA margin should only go up from here,' RK Baheti, CFO of the Vadodara-based company, said
BUSINESS
Aster DM Healthcare to set up another hospital in Bengaluru, invest Rs 480 crore
The hospital in Sarjapur, to be developed in phases, positions Aster among the top three healthcare providers in the region, with a total bed capacity exceeding 2,000
BUSINESS
Glenmark's novel cancer drug gets fast track status from USFDA
The Fast Track status is intended to accelerate the development and review process for drugs addressing serious conditions with unmet medical needs, potentially bringing treatments to patients faster.
BUSINESS
Suven to Divi’s: Indian CDMOs seize opportunity in pivot away from China amid global trade tensions
Concerns around the proposed US Biosecure Act, lingering trade tensions, and the spectre of potential US tariffs are compelling global pharma executives to actively court alternatives, an industry executive told Moneycontrol.
BUSINESS
Covaxin maker Bharat Biotech pivots into cell and gene therapy, eyes cost-effective innovations
The company wants to use its vaccine-making skills in developing CAR-T and gene therapies at a fraction of the cost, aspiring to be a critical part of the cell and gene therapy value chain, said its Chief Development Officer Raches Ella.
BUSINESS
ChrysCapital-backed Corona Remedies files DRHP for Rs 800 crore IPO
The entire offering will be an Offer for Sale by the promoter group, led by Dr Kirtikumar Laxmidas Mehta, and existing investor ChrysCapital's affiliates.
BUSINESS
Aster DM Healthcare completes acquisition of Quality Care India through share swap
The transaction, valued at Rs 849 crore, involved no cash outflow for Aster DM Healthcare, and the merged entity will be jointly controlled by Aster promoters and BCP Asia.
BUSINESS
Healthify launches new weight loss program integrating GLP-1 therapy with lifestyle coaching
The program, developed with input from experts at Stanford, Harvard, and leading Indian endocrinologists, aims to maximize sustainable weight loss outcomes and minimize potential side effects associated with GLP-1 therapies.
BUSINESS
Caesarean procedures rise sharply, comprise 72.5% of deliveries in private hospitals: Study
Since caesarean surgeries are about 30 percent costlier than normal deliveries, they push up insurance premiums in the employers' group health insurance segment, a Prudent Insurance Broking study has said.
BUSINESS
BDR Pharma targeting 2027 for IPO launch, looking to acquire units in US, says CMD Dharmesh Shah
In the past few years, BDR Pharma has spent close to Rs 600 crore and plans to invest another Rs 700 crore to boost growth and acquisitions over the next three years
BUSINESS
Syngene expects slower growth in FY26 on inventory reset, expansion costs
Syngene reported a revenue growth of 4 percent at Rs 3,642 crore for FY25. Profit, however, was down 3%
BUSINESS
'Sense of urgency' among pharma giants to move beyond China: Suven Pharma Chairman
Some global companies have even proposed co-investments to set up manufacturing capacities, Vivek Sharma told Moneycontrol from the US.
BUSINESS
Laurus Labs bets on cell and gene therapies, eyes CDMO role
Laurus aims to leverage India's manufacturing prowess to serve global cell and gene therapy players targeting the Indian market, CEO Satyanarayana Chava has said
BUSINESS
AbbVie enters India oncology market with much-awaited launch of leukemia drug Venetoclax
The move comes as India grapples with a rising burden of AML, particularly among its aging population.
BUSINESS
Venus Remedies gets USFDA boost for potential antibiotic drug VRP-034
The QIDP status, granted by USFDA makes VRP-034 eligible for regulatory benefits including priority FDA review, potential fast-track designation, and an additional five years of market exclusivity in the U.S. upon approval.
BUSINESS
Zydus, Lupin seen weathering generic Myrbetriq court loss, says Elara report
An U.S. District Court recently ruled against Zydus and Lupin, finding Astellas's patent for Myrbetriq was not invalid. Both Indian drugmakers have been selling their generic versions of Myrbetriq "at risk" in the U.S. since the first quarter of fiscal year 2025.
BUSINESS
Cost and access drive international patients to India for CAR-T therapy
CAR-T therapy costs about Rs 50 lakh in India including hospital fees, much less than the Rs 3-4 crore or more (before hospital fees) in US, Germany, Spain, UK, Italy and France.
